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DOI 10.1016/j.chembiol.2011.05.004For an instance of good coming from the
seemingly evil, consider the cannabis
plant. Although treasured by many for its
medicinal properties, this herb is officially
reviled for being the source of hashish and
marijuana, two popular drugs of abuse.
Nevertheless, it is the study of this plant
that has led to the discovery of the canna-
binoid system, a signaling mechanism
present in many cell and tissue types in
the body, affecting a vast range of pro-
cesses from brain development and car-
diovascular function to immune response,
bone growth, pain, hunger, mood, move-
ment, and memory. Recent advances in
understanding this system are now trans-‘‘Everyone realized there’s a reasonwhywehave those receptors,
not just the off chance of one of our predecessors picking up
some cannabis and smoking it.’’ — Aron Lichtmanlating into novel drugs and therapies for
pain, cancer, stroke, and many other
disorders. ‘‘The dopaminergic and sero-
tonergic systems were discovered in the
‘30s, but it has taken us much longer to
discover this system, which is perhaps
just as important,’’ says Israeli biochemist
Raphael Mechoulam, Ph.D., widely con-
sidered the founder of modern cannabi-
noid research. ‘‘It offers a treasure trove
of new medical possibilities waiting to be
unearthed.’’
Opium and coca yielded their chemical
secrets in the 19th and early 20th century,
but it wasn’t until the 1960s that Mechou-
lam’s team at the Weizmann Institute in
Rehovot (with Yehiel Gaoni, Ph.D.) and
later at the Hebrew University in Jerusa-
lem turned the spotlight on cannabis. A
big challenge was obtaining any form of
this illegal plant for research. To tackle
this issue, Mechoulam sought the help of
the Tel Aviv police, who obligingly handed
over to him 5 kg of top-quality smuggled
Lebanese hashish. Later, it turned out
that Mechoulam had broken several druglaws in procuring an illegal substance
without approval from Israel’s Ministry of
Health. In another country, such an act
might have ended in imprisonment and
disgrace; however, this story has a happy
ending. Thanks to his status as a re-
spected researcher, all Mechoulam had
to do was apologize, and, since then, for
the past 40 years, the Ministry has been
providing him all the hashish he needs
for his research. Thus it was that in the
mid 1960s, Mechoulam’s lab isolated
a ‘‘toxic red oil’’ as the main psychoactive
ingredient in cannabis and identified it
as D1-tetrahydrocannabinol (or D1-THC,
later renamed D9-THC). Several othercannabis constituents, which Mechoulam
termed ‘‘cannabinoids,’’ were soon iden-
tified. ‘‘The timing was good,’’ recalls Me-
choulam. ‘‘The ‘flower generation’ was
getting interested in cannabis for entirely
different reasons, and the US government
wanted us to find out if it did anything
nasty.’’
It would take scientists another 20–30
years to start figuring out how these newly
identified compounds act in the body.
‘‘Initially, we thought they acted through
membranes, just like anesthetics or sol-
vents,’’ says University of Aberdeen re-
searcher Roger Pertwee, Ph.D., another
cannabinoid pioneer. This belief was
overturned in 1988, when researchers at
the St. Louis University Medical School
in Missouri found evidence of a cannabi-
noid receptor in the brain. Subsequently,
a team at the National Institutes of Mental
Health in Maryland cloned a G-coupled
protein receptor in brain cells that re-
sponded to cannabinoids, and termed
it CB1. Later, another cannabinoid re-
ceptor, CB2, showed up in immune cells.Chemistry & Biology 18, May 27, 2011These startling findings suggested that
mammals are in fact hard-wired to re-
spond to cannabinoids. Further, it turned
out that the cannabis plant does not
have a monopoly on this type of com-
pound; mammalian cells make them,
too. In 1992, Mechoulam’s group isolated
a substance from brain cells that bound to
cannabinoid receptors; subsequently,
Pertwee’s group in Aberdeen found that
it acted just like THC, the psychoactive
compound in cannabis. This substance
was named anandamide, from ‘‘ananda,’’
Sanskrit for joy or bliss. (Mechoulam jokes
that he first looked for a Hebrew word
meaning ‘‘joy’’ but found mostly syno-
nyms for ‘‘sorrow.’’) The researchers
went on to discover 2-arachidonoyl glyc-
erol (2-AG), another important ‘‘endo’’-
cannabinoid in the body.
It was now obvious that the cannabi-
noid system has an important biological
role. ‘‘Everyone realized there’s a reason
why we have those receptors, not just
the off chance of one of our predecessors
picking up some cannabis and smoking
it,’’ says Aron Lichtman, Ph.D., of the Vir-
ginia Commonwealth University in Rich-
mond. Subsequent studies have shown
that the cannabinoid system is a short-
range, lipid-based signaling mechanism
that helps calm nerve and immune cells
and maintains homeostasis. ‘‘It plays a
general physiological role in brain activity,
reproduction, metabolism, cell prolifera-
tion, stem cell differentiation, and many,
many other functions,’’ says Vincenzo Di
Marzo, Ph.D., a researcher at Italy’s
National Research Council. In the early
stages of many disorders, especially neu-
rodegenerative ones such as stroke, Alz-
heimer’s, or multiple sclerosis (MS), the
cannabinoid system seems to play
a protective role. Anandamide and 2-AG
levels shoot up, activating CB1 and CB2
receptors in the affected areas; this, in
turn, modulates neural and immune ac-
tivity to reduce cell deaths, improve blood
circulation, and reduce inflammation. Inª2011 Elsevier Ltd All rights reserved 553
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cannabinoid system may itself go astray
and make things worse. ‘‘It has a dual
nature, just like the immune system,’’
says Di Marzo.
Exploiting the cannabinoid system for
new therapies has proved challenging.
First, while CB1 activation can help in
many disorders—such as nausea and
vomiting caused by anticancer agents,
cancer pain, and lack of appetite—it is
also responsible for cannabis’ psychoac-
tive effects; i.e., its ‘‘high.’’ However much
some patients may enjoy it, cannabinoid-
induced euphoria is frowned upon by the
medical community. Second, since can-
nabinoid receptors have such diverse
roles, targeting them directly can cause
unwanted effects. Administering THC,
which activates CB1, can cause dizzi-
ness, palpitations, and other problems.
Conversely, the antiobesity drug rimona-
bant, which works by blocking CB1,
seems to increase the risk of anxiety,
depression, and suicide by negating the
receptor’s protective role. Finally, the
cannabinoid system’s dual nature—either
ameliorating or aggravating a disorder—
means that targeting it could have para-
doxical effects. ‘‘For instance, at a low
dose, a cannabinoid will do X, and at
a high dose, it will do the opposite of X,’’
says Beat Lutz, Ph.D., of the University
Medical Center Mainz in Germany. ‘‘De-
pending on the dose, it can increase or
decrease appetite, promote or reduce
anxiety, induce or prevent convulsions.’’
Second-generation strategies may help
avoid some of the problems caused by
external CB1 agonists such as THC.
Compounds that reduce metabolic deg-
radation of endocannabinoids or modu-
late cannabinoid activation via allosteric
sites may give better results. ‘‘Instead
of giving THC and flooding the entire
system, we get a more selective effect,’’
says Pertwee, whose team recently dis-
covered allosteric sites on the CB1
receptor. Psychoactive effects can be
minimized by keeping the drug outside
the brain; for instance, by delivering it as
a local injection or skin patch. Alterna-554 Chemistry & Biology 18, May 27, 2011 ªtively, one could target CB2 alone, which
may help with myocardial or hepatic
ischemia/reperfusion injury, chronic in-
flammatory pain, gastrointestinal inflam-
mation, and liver disorders. Nonpsycho-
active cannabis components such as
cannabidiol (CBD), a powerful antioxidant
that doesn’t bind to either CB1 or CB2,
are also relatively safe. Cannabinoids
also work well as low-dose add-ons to
other therapies such as opiate painkillers
and cancer drugs. For instance, although
THC and CBD by themselves have only
weak antitumor effects, they dramatically
boost the efficacy of classic cancer drugs
such as temozolomide, says Manuel Guz-
ma´n, Ph.D., of the Complutense Univer-
sity in Spain. ‘‘Cannabinoids are ex-
tremely good synergizers,’’ he says.
Combining THC with CBD seems to
give better results than THC alone. This
principle underlies Sativex, one of the
most commercially promising medicines
to emerge from cannabinoid research.
Made by UK-based GW Pharmaceuticals
and delivered as an oro-mucosal spray,
the formulation contains equal parts of
the two compounds along with other
cannabis components. This drug is now
approved in the UK, New Zealand, and
Spain (with 6 other EU countries to follow)
as add-on treatment for symptom im-
provement in patients with spasticity in
MS and in Canada for the relief of neuro-
pathic pain in MS and as an adjunctive
analgesic treatment for cancer patients.
‘‘Clinical trial data demonstrate that Sati-
vex is able to positively affect a wide
variety of clinical symptoms,’’ says the
company’s senior medical advisor Ethan
Russo, MD. ‘‘And it is able to do this
without an attendant ‘high.’’’
Medical marijuana advocates are not
impressed. ‘‘From the patient’s point of
view, Sativex is an inferior product,’’
says Rick Doblin, Ph.D., of the Multi-
disciplinary Association for Psychedelic
Studies in Santa Cruz, California. Doblin
argues that swallowing or spraying iso-
lated cannabinoids—unlike smoking can-
nabis—doesn’t provide all the medicinal
benefits of the whole plant, nor does it2011 Elsevier Ltd All rights reservedact as quickly or make it as easy for the
patient to self-adjust the dose for optimal
effect. UCSF cancer specialist Donald
Abrams,M.D., agrees. ‘‘In cannabis, there
are about 70 other cannabinoids, terpe-
noids, and flavonoids that help synergize,
boost, and regulate the effect of THC,’’ he
says. ‘‘Using just one or two active ingre-
dients from the plant is not ideal.’’ In
a 2007 study, Abrams found that smoked
cannabis relieves HIV-associated chronic
neuropathic pain. The drug has also
shown some benefits for anorexia, nau-
sea, and vomiting in patients under-
going cancer chemotherapy. ‘‘As a cancer
doctor, here I have this one drug that I
can recommend my patients for all their
symptoms,’’ says Abrams. ‘‘Instead of
writing them five prescriptions for ex-
pensive drugs, I write them just one that
they can actually grow themselves.’’
Some researchers disagree. ‘‘When
someone is in pain, we don’t give them
opium to smoke—instead, we take its
active ingredient and give it through the
best route of administration,’’ says Licht-
man, who has developed a specialized
inhaler for delivering THC in metered
doses. Popular support for medical mari-
juana remains high, however. A poll con-
ducted by ABC News and The Washing-
ton Post last year showed that 8 out of
10 Americans supported legalizing mari-
juana for medical use, and nearly half
want the drug to be made legal. Federal
agencies remain strongly opposed to
medical marijuana, but several US states
have passed laws allowing its limited
use. Cannabis’ legal fate is hard to
predict. What is undeniable is that this
plant has been the key to one of the
biggest neurochemical discoveries of
recent times. ‘‘The endocannabinoid sys-
tem plays a role in so many tissues and
organs and is involved in such a variety
of disorders’’ says Di Marzo. ‘‘Irrespective
of whether any useful therapies emerge
from it, it’s one of most important sig-
naling systems ever discovered.’’Chandra Shekhar (chandra@nasw.org) is a science
writer based in Princeton, NJ.
